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Fig S1. MD Scatter plot of log2-fold change (D, x-axis),
against absolute difference in transcript number (M, y-axis).
Differentially expressed genes at q = 0.8 are highlighted in
red.
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Severe macrothrombocytopenia with platelet CD9 deficiency
responsive to romiplostim
The spectrum of inherited platelet disorders with variable
platelet size continues to expand.1,2 Among them,
macrothrombocytopenia cases constitute a subgroup with
different genetic basis, and mild-to-moderate thrombocy-
topenia without major bleeding symptoms. Here we describe
a child with symptomatic severe macrothrombocytopenia
without a genetic aetiology and low platelet CD9 expression
raising the possibility of a new form of inherited
macrothrombocytopenia.
A 6-month-old female presented with diffuse ecchymotic
skin lesions, severe thrombocytopenia (<10 9 109/l) and
giant platelets Fig 1A–D. She has normal growth and devel-
opment without any dysmorphic features. She was unrespon-
sive to intravenous immunoglobulin and steroid treatments.
Bone marrow was normocellular with normal megakaryocyte
density and morphology, and cytogenetic evaluation. Family
history revealed that the parents were first-degree cousins,
originally from Yemen; however, two sisters and the parents
had no history of bleeding with normal platelet counts.
Genetic studies for bone marrow failure and macrothrom-
bocytopenia including glycoprotein IBa (GP1BA), glycopro-
tein IBb(GP1BB), glycoprotein IX (GP9) by Sanger
sequencing revealed no variants. The patient was given
weekly platelet transfusions leading to transient count recov-
ery and resolution of the bleeding symptoms Fig 1E. Platelet
flow cytometry analysis and ristocetin-induced aggregation
studies did not show any abnormalities, as the tested platelets
were the transfused cells.
With no underlying cause for macrothrombocytopenia and
continued dependence on platelet transfusions, the patient was
started on thrombopoietin (TPO) receptor agonist (RA),
eltrombopag after reviewing the potential side-effects with par-
ents. Eltrombopag formulation production was discontinued
by the manufacturer, therefore she began treatment with
another TPO-RA, romiplostim, which is administered subcu-
taneously on a weekly schedule providing platelet counts of
>100 9 109/l with resolution of bleeding symptoms Fig 2A.
The patient has been maintained on romiplostim injections for
9 months with continued giant platelets on the periphery.
Whole exome analysis by next generation sequencing did
not reveal a known variant, but heterozygous mutation in
ankyrin repeat domain 26 (ANKRD26) and homozygous
mutation in RNA component of mitochondrial RNA pro-
cessing endoribonuclease (RMRP) with unknown
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Fig 2. Laboratory observations after starting romiplostim therapy. (A) Platelet count recovery and maintenance on weekly romiplostim treatment.
(B) Moderately decreased ristocetin-induced platelet aggregation in the patient platelet-rich plasm sample. Light blue line represents the patient,
lavender line healthy control and black and green lines negative controls. (C) Similar CD42b expression on platelets from the patient, family
members and a control. MnCHF stands for mean channel fluorescence, reflecting expression intensity of the marker. (D) Significantly decreased
CD9 expression on platelets from the patient in comparison with a control sample. (E) Bone marrow megakaryocyte colony development (910).
(F) Similar CD9 expression patterns at day 14 of the in vitro culture on culture-grown bone marrow megakaryocyte precursors from the patient
before and while on romiplostim therapy and a healthy bone marrow donor.
Fig 1. Clinical and laboratory findings prior to treatment with romiplostim. (A) Prominent ecchymotic skin lesions without appreciable petechiae
on the trunk. (B) Very large platelets on Giemsa-Wright stained peripheral blood smears (9100). (C) Platelet size distribution on Haematology
analyser in a control sample. (D) Platelet size distribution on Haematology analyser in the patient sample. (E) Response to single-donor platelet
transfusions before institution of romiplostim treatment.
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significances, which are not considered to be associated with
functional abnormalities reportedly. Variants of RMRP have
been associated with skeletal dysplasia conditions. Telomere
length was within normal limits in leucocytes. Electron
microscopy revealed normal platelet granule size, density and
distribution. No antibodies against gpIb/gpIX, gpIa/IIa,
gpIIb/IIIa, gpIV, and human leucocyte antigen (HLA) class-I
were detected in the serum. Factor VIII activity, von Wille-
brand factor (vWF) antigen, activity, and multimers were
within normal limits. Once platelet count was >100 9 109/l,
platelet aggregation was performed using ADP, collagen,
thrombin, arachidonic acid, ATP and ristocetin and showed
moderate decrease in ristocetin-induced aggregation with
normal responses to other reagents Fig 2B.
Platelet immunophenotyping was done using platelet-rich
plasma (PRP) samples by staining with several monoclonal
antibodies (Beckman Coulter, Brea, CA, USA) on Beckman
Coulter Gallios flow cytometer (Beckman Coulter). Platelet
CD9 staining was not performed before romiplostim therapy.
Patient serum was co-incubated with the control PRP and
platelet immunophenotyping was performed to test for CD9
expression inhibition. Similarly, CD9 was studied on periph-
eral blood monocytes.
Bone marrow samples were collected after signed consents
were obtained in an Institutional Review Board-approved
study to investigate bone marrow failure syndromes during
planned procedures. Megakaryocyte colony growth was
assessed using archived bone marrow mononuclear cells from
a healthy control, and pre- and on-romiplostim patient sam-
ples. MegaCultTM-C Complete Kit with Cytokines and Mega-
Cult-C staining kit (StemCell Technologies, Inc., Vancouver,
BC, Canada) was used for colony-forming unit-megakary-
ocyte (CFU-MK) evaluation.
Bone marrow CD34+-enriched cells obtained by magnetic
bead separation, were re-suspended in StemSpan SFEM
(Serum free medium) supplemented with StemSpan
Megakaryocyte Expansion Supplement (StemCell Technolo-
gies) and incubated at 37°C and 5% CO2 for 14 days.
Megakaryocyte precursors were harvested on days 7, 10 and
14 and stained with several monoclonal antibodies and anal-
ysed on 10-colour Gallios flow cytometer.
There were subtle changes in platelet CD41, CD61,
CD42a, CD42b, CD40, CD31 and CD62P expression, if any,
when compared to a healthy control or other family member
samples Fig 2C. However, platelet CD9 expression was signif-
icantly decreased Fig 2D. There was no change in platelet
CD9 expression, after PRP from healthy control was co-incu-
bated with patient serum suggesting a lack of blocking anti-
CD9 antibody. Monocyte CD9 expression was within normal
limits. Bone marrow megakaryocyte colonies were generated
Fig 2E and sequential flow cytometric characterisation of the
culture-grown megakaryocyte precursors confirmed their
maturation. There was very minimal CD9 expression
decrease at day 14 of the culture in both patient samples
compared with the control subject.
The presented case here has unique features of severe throm-
bocytopenia with bleeding symptoms, very large platelets, and
significantly decreased platelet CD9 expression. Bernard-Soulier
syndrome (BSS) is a type of macrothrombocytopenia charac-
terised by impaired ristocetin-induced aggregation with variable
platelet counts and bleeding symptoms.3 Decreased platelet CD9
expression was first reported in a series of patients with BSS
without genetic studies.4 Later, a patient with genetically con-
firmed BSS due to GP1BB variant was reported to have
decreased CD42a, CD42b and CD9 expression.5 It could be
debatable, if the presented patient is in the spectrum of BSS.
However, flow cytometric analysis revealed normal platelet
CD42a or CD42b expression in contrast to above-referenced
BSS case, which also had GP1BB mutation, thus, making this
case a form of BSS unlikely.
The patient was responsive to romiplostim treatment. Suc-
cessful responses to TPO-RA in inherited thrombocytopenia
cases, some with macrothrombocytopenia have been
reported.6,7 We investigated, if decreased CD9 expression is
related to romiplostim treatment. Megakaryocyte precursors
developed in vitro did not show significantly decreased CD9
expression in either pre- or on-romiplostim samples exclud-
ing a possible effect of romiplostim. Lack of decreased
monocyte CD9 expression stresses cell-specific nature of CD9
deficiency. We also did not find any evidence of antibody-
mediated CD9 blockade. Therefore, low platelet CD9 expres-
sion maybe a secondary phenomenon that occurs in later
stages of platelet development.
CD9 is a membrane protein in the tetraspanin family
expressed on different tissues with unique roles in platelets.8,9
Crosslinking CD9 and CD42 can stimulate platelets signal
independent of gpIIb/gpIIIa.10 Therefore, it can be speculated
that decreased CD9 may lead to impaired platelet aggrega-
tion. In conclusion, role of CD9 in platelet development, sur-
vival and function warrants further investigation. Decreased
platelet CD9 expression in this patient may represent an
independent anomaly causing a yet undescribed bleeding dis-
order.
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Secondary plasma cell leukaemia treated with single agent
venetoclax
Patients with multiple myeloma (MM) are at risk of develop-
ing secondary Plasma Cell Leukaemia (sPCL), with associated
hyperviscosity. In such patients combination therapies for
MM are associated with a short median overall survival of
just 13 months.1 Translocation (11;14) is reported in 33% of
sPCL and involves the immunoglobulin heavy chain locus on
14q32.2 Selective inhibition of Bcl-2 with venetoclax has
shown single agent activity in MM patients harbouring this
translocation, however, single agent activity has not been
reported in sPCL. We demonstrate a rapid and deep haema-
tologic response with reversal of symptomatic hyperviscosity
in sPCL with single agent venetoclax treatment.
Plasma cell leukaemia occurs in the setting of pre-existing
multiple myeloma (sPCL) or arises as a de novo aggressive
haematological malignancy characterized by circulating
plasma cells > 2 9 109/l in peripheral blood.3 sPCL has a
dismal prognosis with no standard or effective therapy avail-
able. In recent years the frequency of sPCL has increased,1
likely explained by improved overall survival in MM, leading
to a higher prevalence of the disease, and development of
clonal evolution in patients who are treated with multiple
novel agents. sPCL occurs in 18–4% of MM patients and is
associated with immunoglobulin heavy chain (IgH) translo-
cations on locus 14q32 in 80% of cases, the most common
being t(11;14), seen in 25–65% of patients.1 Bcl-2 family pro-
teins are critical regulators of apoptosis with anti-apoptotic
(Mcl-1, Bcl-2, Bcl-xL), multidomain pro-apoptotic (Bax,
Bak) and BH3-only members (Bim, Noxa, Bad).4 MM cells
that harbour t(11;14) express high levels of Bcl-2 relative to
Bcl-xL and Mcl-1.
5 Venetoclax, a first in class oral BH3
mimetic, which selectively inhibits Bcl-2 but not Bcl-xL or
Mcl-1, has shown single agent activity in MM.5 BH3 profil-
ing has previously correctly identified Bcl-2-dependent leu-
kaemias; in this case we apply this method to sPCL.6,7 Single
agent activity of venetoclax has not been reported for pri-
mary or secondary plasma cell leukaemia, although, given the
rate of t(11;14) translocations in this disease it follows that
clinical responses may be achieved and successful combina-
tion therapy with venetoclax in primary PCL has been
reported.8
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